Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 16,489 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Connective Tissue Disorder Clear all
Completed Phase 2 Interventional Results available

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

NCT00623233
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Interventions
Gemcitabine, Bevacizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
16
States / cities
Fayetteville, Arkansas • Fresno, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Oct 17, 2026, 10:36 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

NCT02875548
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epitheliod Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
11
States / cities
Tucson, Arizona • Santa Fe, California • Port Saint Lucie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 17, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

NCT03056755
View directory record Official record
Conditions
Breast Cancer
Interventions
Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
25
States / cities
Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 17, 2026, 10:36 PM EDT
Active, not recruiting No phase listed Observational

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

NCT04990726
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Melanoma, Stage II, Melanoma Stage IV
Interventions
Assessment, Biospecimen Collection, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 10:36 PM EDT
Recruiting No phase listed Observational

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT07175285
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Current standard of care treatment options
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
26
States / cities
La Jolla, California • La Palma, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 17, 2026, 10:36 PM EDT
Terminated Phase 2 Interventional

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543
View directory record Official record
Conditions
PAH
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 17, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea

NCT01025635
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid foam 15%, Vehicle foam
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Fremont, California • Santa Monica, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 17, 2026, 10:36 PM EDT
Recruiting Phase 2 Interventional

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

NCT07155317
View directory record Official record
Conditions
Advanced Acral Melanoma, Advanced Cutaneous Melanoma, Advanced Mucosal Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Acral Melanoma, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Mucosal Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 17, 2026, 10:36 PM EDT
Enrolling by invitation Phase 4 Interventional

Nonhealing Venous Leg Ulcers Treated With a Standard of Care (SoC) Alone or Standard of Care and Dehydrated Human Placenta Tissue (dHPT) With Crossover

NCT07230340
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
Amnion-Intermediate-Chorion, Standard of Care (SOC)
Other · Procedure
Lead sponsor
Cellution Biologics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 10:36 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne

NCT07863193
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Denifanstat, Placebo
Drug · Other
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
12 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Bryant, Arkansas • Fremont, California • Doral, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 17, 2026, 10:36 PM EDT
Terminated Phase 3 Interventional Results available

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

NCT03495921
View directory record Official record
Conditions
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions
Vigil, Irinotecan, Temozolomide
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 17, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

NCT00045006
View directory record Official record
Conditions
Cancer
Interventions
vorinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 17, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging

NCT03761706
View directory record Official record
Conditions
Breast Cancer
Interventions
Engagement in Physical Activity, Questionnaires
Behavioral · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years to 99 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 17, 2026, 10:36 PM EDT
Completed Phase 1Phase 2 Interventional

Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)

NCT00095706
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab (drug), Herceptin (drug)
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
18
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Oct 17, 2026, 10:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Inflammation-Induced CNS Glutamate During Breast Cancer Treatment

NCT02421978
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 17, 2026, 10:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function

NCT03062878
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Chemotherapy Effect
Interventions
Arterial blood pressure, Vascular Ultrasound, Venous blood sample, Skin microcirculatory blood flow
Other
Lead sponsor
Carl Ade, M.S., Ph.D.
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 17, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

NCT00166543
View directory record Official record
Conditions
Breast Cancer
Interventions
TAS-108
Drug
Lead sponsor
SRI International
Industry
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 17, 2026, 10:36 PM EDT
Active, not recruiting Early Phase 1 Interventional

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

NCT04541108
View directory record Official record
Conditions
Solid Tumor
Interventions
Rilvegostomig, Volrustomig, Sabestomig, Pembrolizumab, AZD9592, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
9
States / cities
Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 10:36 PM EDT
Completed Phase 3 Interventional

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

NCT05180708
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
QTORIN 3.9% rapamycin anhydrous gel, Vehicle
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Palo Alto, California • New Haven, Connecticut • Orange Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 17, 2026, 10:36 PM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

NCT01007708
View directory record Official record
Conditions
Onychomycosis
Interventions
IDP-108, Vehicle
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
36
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 17, 2026, 10:36 PM EDT
Completed Early Phase 1 Interventional

S-equol in Women With Triple Negative Breast Cancer

NCT02352025
View directory record Official record
Conditions
Breast Cancer
Interventions
S-equol
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 17, 2026, 10:36 PM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 17, 2026, 10:36 PM EDT
Not listed No phase listed Observational

Predicting Chronic Pain Following Breast Surgery

NCT04967352
View directory record Official record
Conditions
Chronic Pain, Opioid Use, Breast Pain, Breast Cancer
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 17, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients

NCT03796052
View directory record Official record
Conditions
Ichthyosis, Pruritus
Interventions
Avena Sativa Skincare Regimen
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 17, 2026, 10:36 PM EDT